Crestor

Hyperlipoproteinemia Type III, Hardening of the Arteries, Hyperlipidemia + 22 more

Treatment

16 FDA approvals

20 Active Studies for Crestor

What is Crestor

Rosuvastatin

The Generic name of this drug

Treatment Summary

Rosuvastatin, also known as Crestor, is a medication used to reduce the risk of cardiovascular disease by lowering cholesterol levels in the body. It belongs to a class of drugs called statins, which block the liver's production of cholesterol. It is commonly prescribed following cardiovascular events and to people with a moderate to high risk of developing cardiovascular disease. Rosuvastatin is known to be the most potent statin drug. It is generally effective and well-tolerated with minimal side effects or long-term effects. It is also less likely to interact with other medications compared to some other statins.

Crestor

is the brand name

image of different drug pills on a surface

Crestor Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Crestor

Rosuvastatin

2003

441

Approved as Treatment by the FDA

Rosuvastatin, otherwise known as Crestor, is approved by the FDA for 16 uses including primary Hyperlipidemia and Homozygous Familial Hypercholesterolaemia (HoFH) .

primary Hyperlipidemia

Homozygous Familial Hypercholesterolaemia (HoFH)

Hypertriglyceridemias

Coronary Artery Disease (CAD)

Helps manage Coronary Artery Disease (CAD)

Dyslipidemias

Dysbetalipoproteinemia

Heart Disease

Heterozygous Familial Hypercholesterolemia (HeFH)

Hyperlipidemia

Homozygous Familial Hypercholesterolemia

Hypertriglyceridemia

Hypercholesterolemia

Hardening of the Arteries

Helps manage Atherosclerosis

Coronary Disease

Helps manage Coronary Artery Disease (CAD)

Atherosclerotic Cardiovascular Diseases

Hyperlipoproteinemia Type III

Effectiveness

How Crestor Affects Patients

Rosuvastatin is a drug used to lower cholesterol. It reduces total cholesterol, LDL-cholesterol, Apolipoprotein B, non-HDL-cholesterol, and triglyceride levels while increasing HDL-cholesterol levels. High LDL-cholesterol, low HDL-cholesterol, and high triglyceride levels can lead to an increased risk of atherosclerosis and cardiovascular disease. Taking rosuvastatin can reduce this risk and decrease the chances of having a major cardiovascular event such as a heart attack, stroke, or coronary death. However, there is a risk of muscle pain, liver enzyme abnormalities, and changes in

How Crestor works in the body

Rosuvastatin works by blocking an enzyme that helps create cholesterol. When this happens, the liver produces more low density lipoprotein (LDL) receptors, which help pull LDL out of the blood. This leads to a decrease in LDL and very low density lipoprotein (VLDL) in the bloodstream. Studies have also shown that rosuvastatin has additional benefits outside of just cholesterol-lowering, such as improving the stability of atherosclerotic plaques, reducing oxidative stress, and inhibiting the thrombogenic response. It also affects leukocyte trafficking and T cell activation by binding to a

When to interrupt dosage

The measure of Crestor is contingent upon the diagnosed state, such as Diet, Dysbetalipoproteinemia and Heart Disease. The amount of dosage differs, as per the procedure of administration laid out in the table below.

Condition

Dosage

Administration

Hyperlipoproteinemia Type III

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hardening of the Arteries

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hyperlipidemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Coronary Disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Primary Hypercholesterolemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Physical Activity

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Cardiovascular Events

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Diet

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

cholesterol

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Lipid-Lowering Therapy

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypertensive disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Venous Thrombosis

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

High Cardiovascular Risk

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypertriglyceridemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Heart Disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypercholesterolemia

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Major Adverse Cardiovascular Events

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Hypertensive disease

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Dyslipidemias

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Atherosclerotic Cardiovascular Diseases

, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 5.2 mg, 20.8 mg, 41.7 mg, 10.4 mg

Oral, , Tablet, film coated - Oral, Tablet, film coated, Tablet, coated, Tablet, coated - Oral, Tablet - Oral, Tablet, Capsule, Capsule - Oral

Warnings

Crestor Contraindications

Condition

Risk Level

Notes

Breast Milk Production

Do Not Combine

Pulse Frequency

Do Not Combine

Liver Failure, Acute

Do Not Combine

There are 20 known major drug interactions with Crestor.

Common Crestor Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Rosuvastatin.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Rosuvastatin.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Rosuvastatin.

Carbamazepine

Major

The metabolism of Carbamazepine can be decreased when combined with Rosuvastatin.

Clonidine

Major

The metabolism of Clonidine can be decreased when combined with Rosuvastatin.

Crestor Toxicity & Overdose Risk

Generally, this drug is safe to take. Common side effects may include muscle pain, constipation, exhaustion, stomach ache, and nausea. Less common side effects include damage to the muscles or liver. Asian patients may need a lower dosage to avoid toxicity, as studies show they absorb the drug more quickly than those of Caucasian descent.

image of a doctor in a lab doing drug, clinical research

Crestor Novel Uses: Which Conditions Have a Clinical Trial Featuring Crestor?

94 studies are currently examining the utility of Crestor in providing Postoperative Thromboembolism prevention, Hypertriglyceridemias management and Cardiovascular Event mitigation.

Condition

Clinical Trials

Trial Phases

other lipid-lowering therapies not suitable

0 Actively Recruiting

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Hypercholesterolemia

4 Actively Recruiting

Phase 1, Phase 3

Hypertensive disease

3 Actively Recruiting

Not Applicable, Phase 3

Coronary Disease

1 Actively Recruiting

Not Applicable

Hardening of the Arteries

18 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3

Homozygous Familial Hypercholesterolemia

2 Actively Recruiting

Phase 3

Cardiovascular Events

4 Actively Recruiting

Not Applicable

Dyslipidemias

1 Actively Recruiting

Phase 2

Primary Prevention of Cardiovascular Diseases

1 Actively Recruiting

Not Applicable

Hyperlipoproteinemia Type III

0 Actively Recruiting

Atherosclerotic Cardiovascular Diseases

12 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 4

Drug Combinations

0 Actively Recruiting

cholesterol

4 Actively Recruiting

Phase 3, Not Applicable

Hypertensive disease

27 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3

Primary Hypercholesterolemia

8 Actively Recruiting

Phase 3, Phase 2, Not Applicable

Major Adverse Cardiovascular Events

0 Actively Recruiting

Hyperlipidemia

0 Actively Recruiting

Heart Disease

37 Actively Recruiting

Not Applicable, Phase 3, Phase 2, Phase 1, Phase 4, Early Phase 1

diet and exercise

0 Actively Recruiting

Crestor Reviews: What are patients saying about Crestor?

5

Patient Review

11/28/2021

Crestor for High Cholesterol

Crestor was my third try at a statin medication, and it finally worked without any awful side effects. I take a very low dose, but it's kept my cholesterol in the normal range for about ten years now.

3.3

Patient Review

10/10/2022

Crestor for Increased Triglycerides and Cholesterol

I developed shoulder pain a few months after starting to take Crestor 10mg. After I stopped taking the medication for a short while, the pain went away. My doctor told me to slowly start taking it again because my numbers were excellent. However, recently after going back on the medication, I've been having gastrointestinal issues and diarrhea. Has anyone else experienced this?

2.7

Patient Review

3/28/2022

Crestor for Treatment to Prevent a Heart Attack

I developed bells palsy after just three months of taking Crestor, which my doctor had prescribed for high cholesterol. After doing some research, I found that many statin drugs are linked to causing this condition. For me, the benefits did not outweigh the risks.

2.3

Patient Review

8/30/2022

Crestor for High Cholesterol

After three years of taking this medication, it left me with muscle problems that required the help of a cane to walk. Once I stopped taking it, though, I was able to walk just fine within five days.

2.3

Patient Review

8/25/2022

Crestor for High Cholesterol

I've only been taking this medication for a short while, but the leg pain it's caused is unbearable. I may have to stop taking it as a result.

2

Patient Review

7/17/2022

Crestor for Treatment to Prevent a Heart Attack

Crestor caused me so much pain in my knees and hips. I couldn't even walk without being in agony. Thankfully, I stopped taking it after two months. Do your research before starting any medication!

1.7

Patient Review

8/15/2022

Crestor for Increased Triglycerides and Cholesterol

I've been experiencing a range of troubling side effects since taking this medication, including forgetting words, losing things multiple times per day, and muscle pain and weakness. I'm going to stop taking the drug today in hopes that my symptoms will improve.

1.3

Patient Review

11/27/2021

Crestor for Slow Progression of Disease of the Arteries of the Heart

I was not informed of the possible side effects of this medication. I have been taking Crestor for seven weeks and have noticed weakness in my quadriceps, fasciculations in my right leg, and increased back pain. My blood sugar has also risen with no prior history of diabetes. I stopped taking the medication nine days ago and am still waiting to see if the side effects are reversible.

1

Patient Review

8/15/2022

Crestor for Increased Triglycerides and Cholesterol

This drug has caused me a lot of problems. I've forgotten words mid sentence, have had severe leg pain and muscle loss, and become much more irritable. My gums have also started to deteriorate; this is on top of sugar cravings and other issues. If you're considering taking this drug, please weigh the pros and cons very carefully.

1

Patient Review

8/15/2022

Crestor for Increased Triglycerides and Cholesterol

I felt so dizzy and in pain that I could barely move. My mind was fuzzy and it was hard to communicate. The pain was unbearable. I'd rather control my ldl through diet and exercise than take this again.

1

Patient Review

12/4/2021

Crestor for Prevention of Transient Ischemic Attacks

I have been on this medication for nine months and it has caused me to be hospitalized six times. The side effects are severe dizziness, heart palpitations, high blood pressure, ankle pain, headaches, and flu-like symptoms. I stopped taking the medication and almost all of the symptoms went away. All of the doctors thought I was crazy. Do not ever take this medication!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about crestor

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the most common side effect of Crestor?

"Common side effects of Crestor include headaches, muscle aches and pains, abdominal pain, weakness, and nausea. Other side effects that have been reported include memory loss and confusion. If you experience any side effects, tell your doctor."

Answered by AI

What does Crestor do to your body?

"Rosuvastatin may also be used to prevent certain types of heart problems, and to reduce the risk of stroke and heart attack.

Rosuvastatin is used to lower bad cholesterol, raise good cholesterol, and prevent heart problems."

Answered by AI

What foods should be avoided when taking Crestor?

"Do not eat foods that are high in fat or cholesterol as it will make the rosuvastatin less effective. Do not drink alcohol as it will raise triglyceride levels and may cause liver damage. Some antacids can reduce the body's ability to absorb rosuvastatin."

Answered by AI

Should I take Crestor at night?

"You can take CRESTOR at any time of day, with or without food."

Answered by AI

Clinical Trials for Crestor

Image of University of California, San Diego in San Diego, United States.

BPCARE Intervention for High Blood Pressure

18+
All Sexes
San Diego, CA

The goal of this randomized clinical trial is to determine whether a community health worker-delivered, multi-component behavioral intervention can improve antihypertensive medication adherence and blood pressure control among adult refugees with hypertension who are prescribed antihypertensive medications. The main questions it aims to answer are: 1. Does participation in the BPCARE intervention improve antihypertensive medication adherence compared to enhanced usual care? 2. Does participation in the BPCARE intervention improve blood pressure control and persistence over time compared to enhanced usual care? Researchers will compare participants randomized to the BPCARE intervention to those receiving enhanced usual care (hypertension information and a home blood pressure monitor) to determine the effects on medication adherence, blood pressure control, and persistence. Participants will: * Be randomly assigned to either the BPCARE intervention or enhanced usual care * Receive hypertension education and a home blood pressure monitor * Participate in community health worker-delivered sessions that include hypertension and medication education, motivational interviewing, problem-solving, and action planning (intervention arm only) * Complete questionnaires assessing medication adherence and related psychosocial factors * Have blood pressure monitored using connected home blood pressure devices * Complete pill counts to assess medication adherence over a nine-month follow-up period

Recruiting
Has No Placebo

University of California, San Diego (+1 Sites)

Image of Centre EPIC in Montreal, Canada.

Maple Syrup for Endurance Cycling Performance

18 - 45
Male
Montreal, Canada

The goal of this clinical trial is to learn whether maple syrup can be used as a natural carbohydrate source to help trained male cyclists perform better during long-duration cycling. The study also aims to learn how different amounts of maple syrup affect energy use in the body, stomach comfort, and feelings of effort and fatigue. The main questions the study aims to answer are: * Does consuming more carbohydrate from maple syrup help participants finish a 20-kilometer cycling time trial faster? * How do different amounts of maple syrup change how the body uses carbohydrates and fats during long exercise? * Are higher amounts of maple syrup easy for participants to tolerate without stomach problems? Researchers will compare four drinks: 1. A placebo drink (a look-alike drink with no calories), 2. A drink that provides 60 grams of carbohydrate per hour, 3. A drink that provides 90 grams per hour, and 4. A drink that provides 120 grams per hour. They will compare these drinks to see whether higher carbohydrate amounts lead to better cycling performance and how each dose affects comfort and metabolism. Participants will: * Attend a screening visit that includes a health check and a glucose tolerance test. * Complete a fitness test to measure their aerobic capacity and practice the cycling tests used in the study. * Take part in four separate exercise sessions in random order. Each session includes: * Drinking one of the four study beverages during 2 hours of steady cycling, * Completing two short, all-out 6-second sprints during the ride, * Completing a 20-kilometer cycling time trial as fast as possible, * Reporting stomach symptoms and perceptions of effort, * Providing breath, blood, urine, and sweat samples so researchers can measure how their body uses fuel. All drinks will look, taste, and smell similar so participants cannot tell which one they are receiving. Meals before each session will be provided to keep conditions the same across visits. This study may help athletes and active people choose natural carbohydrate sources that support both performance and comfort during long endurance exercise. The findings may also guide future research on the use of maple syrup as a sports nutrition option.

Waitlist Available
Paid Trial

Centre EPIC

Jonathan Tremblay, PhD

Mitacs

Image of National Association of Pasifika Organizations in Fayetteville, United States.

PILI Pasifika Program for Cardiometabolic Conditions

18+
All Sexes
Fayetteville, AR

In this study, the investigators are testing the effectiveness and implementation of the Community Health Workers (CHW)-delivered PILI Pasifika Program (PPP) Standard Facilitation or Enhanced Facilitation across 3 regions, the U.S. Affiliated Pacific Islands (USAPI), the continental U.S., and Hawai'i, among 600 Native Hawaiian and Pacific Islander (NHPI) participants in two settings, (clinical and non-clinical) over a 3-year period. The PPP is a 3-month lifestyle intervention that includes a Social Determinants of Health (SDOH) component and was NHPI-adapted from the Diabetes Prevention Program's Lifestyle Program, renamed to the PILI Lifestyle Program (PLP), which demonstrated effectiveness in improving weight, blood pressure, physical activity, and diet among NHPIs. The PPP consists of 8 lifestyle lessons and 4 SDOH activities delivered over a 3-month period. The investigators will conduct an effectiveness-implementation hybrid type 2 trial using a 3 (Region) x 2 (Setting) x 2 (Delivery Mode) factorial design. The long-term objective of this study is threefold: 1. To conduct an effectiveness-implementation hybrid 2 trial to test the effects of the PPP implementation strategies across different settings and modes of delivery among 600 NHPIs at risk for cardiometabolic-related conditions using an NHPI-approved and adapted evaluation framework. The investigators will also assess and compare the cost-effectiveness of the CHW-delivered PPP-Standard Facilitation and PPP-Enhanced Facilitation to support long-term sustainability. 2. To conduct a longitudinal Social Determinants of Health (SDOH) survey embedded within the trial to examine the reliability and validity of indices from 5 adapted SDOH instruments and to assess the associations between SDOH variables and chronic disease risk among NHPIs. 3. To implement and evaluate the contextually-based CHW training program on PPP delivery.

Waitlist Available
Has No Placebo

National Association of Pasifika Organizations (+1 Sites)

Joseph K Kaholokula, PhD

Have you considered Crestor clinical trials?

We made a collection of clinical trials featuring Crestor, we think they might fit your search criteria.
Go to Trials
Image of Rush University Medical Center in Chicago, United States.

Food is Medicine for High Blood Pressure

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to assess nutrition incentives and produce vouchers to measure the impacts of food insecurity-related chronic health conditions in adults with hypertension and/or diabetes. The main questions it aims to answer are: * Does participation increase fruit and vegetable consumption for participants? * Does participation reduce individual and household food insecurity? * Does participation reduce healthcare utilization and associated costs? * Does participation lead to improvements in diet-related health outcomes (e.g., hypertension, diabetes)? * Does participation support the local economy by increasing participant spending at local food vendors? Participants will: * Receive 6 months home delivered produce prescription boxes * Receive 6 months match of produce vouchers * Receive nutrition education and participate in Chronic Disease Self-Management classes

Waitlist Available
Has No Placebo

Rush University Medical Center

Traci Simmons, DrPHc, MPH

Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Have you considered Crestor clinical trials?

We made a collection of clinical trials featuring Crestor, we think they might fit your search criteria.
Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Rosuvastatin for Cancer-Associated Blood Clots

18+
All Sexes
Boston, MA

Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.

Phase 4
Waitlist Available

Brigham and Women's Hospital (+1 Sites)

Image of UA Collaboratory for Metabolic Disease Prevention & Treatment in Tucson, United States.

Community Health Intervention for Fatty Liver and Heart Diseases

18+
All Sexes
Tucson, AZ

CVD is the leading cause of death among individuals with MASLD, a risk factor for liver cancer. In Southern Arizona, CVD and cancer (including liver and gastric cancer) are among the leading causes of death for Mexican-origin adults.1 Given Mexican-origin adults' disproportionate burden of CVD-related mortality37 and higher rates of MASLD compared to other ethnic/racial groups; we urgently need to develop contextually tailored strategies for management of CVD risk factors and outcomes. Thus, the purpose of this study is to examine the acceptability and feasibility of a community health worker (CHW)-led intervention aimed to increase cardiovascular risk awareness and promote lifestyle modifications among Mexican-origin adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Southern Arizona region. The proposed project has the potential to improve health outcomes for this vulnerable population and contribute to the ACS-CHERC's overarching goal of improving health equity for Hispanic communities and family caregivers.

Recruiting
Has No Placebo

UA Collaboratory for Metabolic Disease Prevention & Treatment

Have you considered Crestor clinical trials?

We made a collection of clinical trials featuring Crestor, we think they might fit your search criteria.
Go to Trials